Abstract: Objective:To study the clinical efficacy and safety of anti-thymocyte globulin (ATG) and basiliximab in donor heart organ death (DCD) donor kidney transplantation.Methods:We selected 56 cases of DCD donors and 112 kidneys,and 112 patients with renal transplantation from October 2014 to February 2017 were selected as subjects,randomly divided into control group and observation group ,each group of 56 cases.Patients in the control group received postoperative baclitaxel immunotherapy, and the observation group received ATG immunotherapy.compared two groups after surgery of the graft recovery rate (DGF), acute rejection and other complications,and compared the graft survival rate and patient survival rate in one year after operation.Results:The incidence of DGF and the time of hospitalization were significantly lower in the observation group than in the control group (P<0.05). The incidence of hospital infection and impaired liver function in the observation group was significantly lower than that in the control group (P<0.05) The incidence of DGF was significantly lower in the patients than in the control group (P<0.05). There was no significant difference in the incidence of complications such as acute rejection, post-discharge infection, thrombocytopenia, anemia, leukopenia and newly diagnosed diabetes mellitus(P>0.05). There was no significant difference in the survival rate and graft survival rate between the two groups (P>0.05).Conclusion:ATG can significantly reduce the incidence of DGF after cardiac transplantation in patients with heart DCD, and promote the recovery of patients after operation, especially for high-risk patients, which is worthy of clinical promotion